PD Dr. Markus Eckstein

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Same same but different: A Web-based deep learning application revealed classifying features for the histopathologic distinction of cortical malformations (2020) Kubach J, Muhlebner-Fahrngruber A, Soylemezoglu F, Miyata H, Niehusmann P, Honavar M, Rogerio F, et al. Journal article Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients (2019) Abdulrahman A, Eckstein M, Jung R, Guzman J, Weigelt K, Serrero G, Yue B, et al. Journal article DAPK1 loss triggers tumor invasion in colorectal tumor cells (2019) Steinmann S, Kunze P, Hampel C, Eckstein M, Bertram Bramsen J, Muenzner JK, Carlé BE, et al. Journal article Anln and tle2 in muscle invasive bladder cancer: A functional and clinical evaluation based on in silico and in vitro data (2019) Wu S, Nitschke K, Heinkele J, Weis CA, Worst TS, Eckstein M, Porubsky S, Erben P Journal article PD-L1 assessment in urothelial carcinoma: a practical approach (2019) Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T Journal article, Review article Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stöhr R, Eckstein M, Zinnall U, et al. Journal article Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution